|June 13, 2017 12:30 p.m. ET|
|May 01, 2017 5:00 p.m. ET|
|February 27, 2017 5:00 p.m. ET|
|November 03, 2016 5:00 p.m. ET|
|October 10, 2016 1:00 p.m. ET|
|Exelixis, Inc. at the European Society for Medical Oncology (ESMO) 2016 Congress|
Exelixis co-hosted an investor and media briefing at the ESMO 2016 Congress. During the 90 minute event, the company’s management team and invited guests reviewed data for cabozantinib presented at ESMO, including the results of the CABOSUN phase 2 randomized trial. The event also included a panel discussion with Drs. Toni K. Choueiri (Dana-Farber), Nizar Tannir (MD Anderson Cancer Center) and Sumanta Pal (City of Hope).
|August 03, 2016 5:00 p.m. ET|